Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Gil-Farina

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Nature Biotechnology|November 27, 2023
Tracing the fate of AAV vectors in the bodyNerea Zabaleta, Irene Gil-Farina
Current Opinion in Virology|July 31, 2016
Interaction of vectors and parental viruses with the host genomeIrene Gil-Farina, Manfred Schmidt
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 16, 2016
Reply to "Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV"Manfred Schmidt, Irene Gil-Farina, Hildegard Büning
Briefings in Bioinformatics|October 14, 2017
Systematic comparative study of computational methods for T-cell receptor sequencing data analysisSaira Afzal, Irene Gil-Farina, Richard Gabriel, et al.
Human Gene Therapy|August 22, 2017
Lentiviral Vector Promoter is Decisive for Aberrant Transcript FormationSimone J Scholz, Raffaele Fronza, Cynthia C Bartholomä, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2020
AdrA as a Potential Immunomodulatory Candidate for STING-Mediated Antiviral Therapy That Required Both Type I IFN and TNF-α ProductionEstefania Rodriguez-Garcia, Nerea Zabaleta, Irene Gil-Farina, et al.
Molecular Therapy. Methods & Clinical Development|March 24, 2025
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIIIJohannes Lengler, Markus Weiller, Franziska Horling, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 8, 2016
Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and PatientsIrene Gil-Farina, Raffaele Fronza, Christine Kaeppel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 12, 2016
Transient Expression of Transgenic IL-12 in Mouse Liver Triggers Unremitting Inflammation Mimicking Human Autoimmune HepatitisIrene Gil-Farina, Marianna Di Scala, Eduardo Salido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancerLucia Vanrell, Marianna Di Scala, Laura Blanco, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Nature Biotechnology|November 27, 2023
Tracing the fate of AAV vectors in the bodyNerea Zabaleta, Irene Gil-Farina
Current Opinion in Virology|July 31, 2016
Interaction of vectors and parental viruses with the host genomeIrene Gil-Farina, Manfred Schmidt
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 16, 2016
Reply to "Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV"Manfred Schmidt, Irene Gil-Farina, Hildegard Büning
Briefings in Bioinformatics|October 14, 2017
Systematic comparative study of computational methods for T-cell receptor sequencing data analysisSaira Afzal, Irene Gil-Farina, Richard Gabriel, et al.
Human Gene Therapy|August 22, 2017
Lentiviral Vector Promoter is Decisive for Aberrant Transcript FormationSimone J Scholz, Raffaele Fronza, Cynthia C Bartholomä, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2020
AdrA as a Potential Immunomodulatory Candidate for STING-Mediated Antiviral Therapy That Required Both Type I IFN and TNF-α ProductionEstefania Rodriguez-Garcia, Nerea Zabaleta, Irene Gil-Farina, et al.
Molecular Therapy. Methods & Clinical Development|March 24, 2025
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIIIJohannes Lengler, Markus Weiller, Franziska Horling, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 8, 2016
Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and PatientsIrene Gil-Farina, Raffaele Fronza, Christine Kaeppel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 12, 2016
Transient Expression of Transgenic IL-12 in Mouse Liver Triggers Unremitting Inflammation Mimicking Human Autoimmune HepatitisIrene Gil-Farina, Marianna Di Scala, Eduardo Salido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancerLucia Vanrell, Marianna Di Scala, Laura Blanco, et al.
Pageof 3